Archive
Home / Media Centre / Archive
Here you can find the archive of all Press Releases prior to 2022
Filter by date:
Showing 1107 press releases before 2022
-
AstraZeneca and MSD rapidly advance Lynparza in Japan with a second regulatory submission
-
US FDA approves new easy-to-use, once-weekly Bydureon BCise injectable medicine for patients with type-2 diabetes
-
US FDA accepts regulatory submission for Lynparza in metastatic breast cancer and grants Priority Review
-
US FDA accepts supplemental Biologics License Application for Imfinzi in locally advanced unresectable non-small cell lung cancer
-
AstraZeneca shares its comprehensive scientific approach at the World Conference on Lung Cancer 2017
-
The European Medicines Agency accepts marketing authorisation application for Imfinzi in locally-advanced unresectable non-small cell lung cancer
-
Tagrisso granted breakthrough therapy designation by US FDA for the 1st-line treatment of patients with EGFR mutation-positive non-small cell lung cancer
-
Bevespi Aerosphere demonstrates statistically significant improvement in lung function in patients with COPD
-
Bydureon EXSCEL trial demonstrates favourable cardiovascular (CV) safety profile and fewer CV events in patients with type-2 diabetes at wide range of CV risk
-
AstraZeneca and Aspen enter agreement for remaining rights to anaesthetics medicines
Latest articles and press releases
All of our latest press releases and articles are available to explore
